Page 12 - Management of advanced kidney cancer: KCRNC

hotte et al

70. Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib vs. sorafenib in 86. Mason RJ, Wood L, Kapoor N, et al. Kidney Cancer Research Network of Canada (KCRNC) consensus
advanced renal cell carcinoma (AXIS): A randomized phase 3 trial. Lancet 2011;378:1931-9. statement on the role of cytoreductive nephrectomy for patients with metastatic renal cell carcinoma.
https://doi.org/10.1016/S0140-6736(11)61613-9 Can Urol Assoc J 2019;13:166-174. https://doi.org/10.5489/cuaj.5786
71. Wells JC, Stukalin I, Norton C, et al. Third-line targeted therapy in metastatic renal cell carcinoma: Results 87. Méjean A, Ravaud A, Thezenas S, et al. Sunitinib alone or after nephrectomy in metastatic renal cell
from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol 2017;71:204-9. carcinoma. N Engl J Med 2018;379:417-27. https://doi.org/10.1056/NEJMoa1803675
https://doi.org/10.1016/j.eururo.2016.05.049 88. Bex A, Mulders P, Jewett M, et al. Comparison of immediate vs. deferred cytoreductive nephrectomy in
72. Albiges L, Fay AP, Xie W, et al. Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic patients with synchronous metastatic renal cell carcinoma receiving sunitinib: The SURTIME randomized
renal cell carcinoma. Eur J Cancer 2015;51:2580-6. https://doi.org/10.1016/j.ejca.2015.08.017 clinical trial. JAMA Oncol 2019;5:164-170. https://doi.org/10.1001/jamaoncol.2018.5543
73. Motzer RJ, Hutson TE, Glen H, et al. Lenvatinib, everolimus, and the combination in patients with metastatic 89. Eggener SE, Yossepowitch O, Pettus JA, et al. Renal cell carcinoma recurrence after nephrectomy
renal cell carcinoma: A randomized, phase 2, open-label, multicenter trial. Lancet Oncol 2015;16:1473-82. for localized disease: Predicting survival from time of recurrence. J Clin Oncol 2006;24:3101-6.
https://doi.org/10.1016/S1470-2045(15)00290-9 https://doi.org/10.1200/JCO.2005.04.8280
74. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carci - 90. Breau RH, Blute ML. Surgery for renal cell carcinoma metastases. Curr Opin Urol 2010;20:375-81.
noma: A double-blind, randomized, placebo-controlled, phase 3 trial. Lancet 2008;372:449-56. https://doi.org/10.1097/MOU.0b013e32833c7ada
https://doi.org/10.1016/S0140-6736(08)61039-9 91. Kim DY, Karam JA, Wood CG. Role of metastasectomy for metastatic renal cell carcinoma in the era
75. Gore ME, Szczylik C, Porta C, et al. Safety and efficacy of sunitinib for metastatic renal-cell carci - of targeted therapy. World J Urol 2014;32:631-42. https://doi.org/10.1007/s00345-014-1293-6
noma: An expanded-access trial. Lancet Oncol 2009;10:757-63. https://doi.org/10.1016/S1470- 92. Siva S, Pham D, Gill S, et al. A systematic review of stereotactic radiotherapy ablation for primary renal
2045(09)70162-7 cell carcinoma. BJU Int 2012;110:E737-43. https://doi.org/10.1111/j.1464-410X.2012.11550.x
76. Stadler WM, Figlin RA, McDermott DF, et al. Safety and efficacy results of the advanced renal cell 93. Siva S, Pham D, Kron T, et al. Stereotactic ablative body radiotherapy for inoperable primary kidney
carcinoma sorafenib expanded access program in North America. Cancer 2010;116:1272-80. cancer: A prospective clinical trial. BJU Int 2017;120:623-30. https://doi.org/10.1111/bju.13811
https://doi.org/10.1002/cncr.24864 94. Cheung P, Thibault I, Bjarnason GA. The emerging roles of stereotactic ablative radiotherapy for metastatic
77. Dutcher JP, de Souza P, McDermott D, et al. Effect of temsirolimus vs. interferon-alpha on outcome of renal cell carcinoma. Current Opin Support Palliat Care 2014;8:258-64. https://doi.org/10.1097/
patients with advanced renal cell carcinoma of different tumor histologies. Med Oncol 2009;26:202-9. SPC.0000000000000074
https://doi.org/10.1007/s12032-009-9177-0 95. Kothari G, Foroudi F, Gill S, et al. Outcomes of stereotactic radiotherapy for cranial and extracranial
78. Choueiri TK, Plantade A, Elson P, et al. Efficacy of sunitinib and sorafenib in metastatic papillary metastatic renal cell carcinoma: a systematic review. Acta Oncol 2015;54:148-57. https://doi.org/1
and chromophobe renal cell carcinoma. J Clin Oncol 2008;26:127-31. https://doi.org/10.1200/ 0.3109/0284186X.2014.939298
JCO.2007.13.3223 96. Clinicaltrials.gov. Stereotactic radiotherapy for metastatic kidney cancer being treated with sunitinib.
79. Buti S, Bersanelli M, Maines F, et al. First-line pazopanib in non-clear-cell renal carcinoma: The NCT02019576.
Italian retrospective multicenter PANORAMA Study. Clin Genitourin Cancer 2017;15:e609-14. 97. Cheung P. Stereotactic body radiotherapy for oligoprogressive cancer. B J Radiol 2016;89:20160251.
https://doi.org/10.1016/j.clgc.2016.12.024 https://doi.org/10.1259/bjr.20160251
80. Tannir NM, Jonasch E, Albiges L, et al. Everolimus vs. sunitinib prospective evaluation in metastatic non-clear 98. Sahi C, Knox JJ, Clemons M, et al. Renal cell carcinoma bone metastases: Clinical advances. Ther Adv
cell renal cell carcinoma (ESPN): A randomized, multicenter, phase 2 trial. Eur Urol 2016;69:866-74. Med Oncol 2010;2:75-83. https://doi.org/10.1177/1758834009358417
https://doi.org/10.1016/j.eururo.2015.10.049 99. Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronic acid vs. placebo in the treatment of skeletal
81. Armstrong AJ, Halabi S, Eisen T, et al. Everolimus vs. sunitinib for patients with metastatic non-clear metastases in patients with lung cancer and other solid tumors: A phase 3, double-blind, randomized trial
cell renal cell carcinoma (ASPEN): A multicentrer, open-label, randomized, phase 2 trial. Lancet Oncol — the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 2003;21:3150-7.
2016;17:378-88. https://doi.org/10.1016/S1470-2045(15)00515-X https://doi.org/10.1200/JCO.2003.04.105
82. Nanus DM, Garino A, Milowsky MI, et al. Active chemotherapy for sarcomatoid and rapidly progressing 100. Lipton A, Colombo-Berra A, Bukowski RM, et al. Skeletal complications in patients with bone metastases
renal cell carcinoma. Cancer 2004;101:1545-51. https://doi.org/10.1002/cncr.20541 from renal cell carcinoma and therapeutic benefits of zoledronic acid. Clin Cancer Res 2004;10:S6397-
83. Michaelson MD, McKay RR, Werner L, et al. Phase 2 trial of sunitinib and gemcitabine in patients 403. https://doi.org/10.1158/1078-0432.CCR-040030
with sarcomatoid and/or poor-risk metastatic renal cell carcinoma. Cancer 2015;121:3435-43. 101. Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab vs. zoledronic acid in
https://doi.org/10.1002/cncr.29503 the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer)
84. McDermott DF, Choueri TK, Motzer RJ, et al. CheckMate 214 post-hoc analyses of nivolumab plus or multiple myeloma. J Clin Oncol 2011;29:1125-32. https://doi.org/10.1200/JCO.2010.31.3304
ipilimumab or sunitinib in IMDC intermediate/poor-risk patients with previously untreated advanced renal 102. Canadian Cancer Society. Available at: http://www.cancer.ca. Accessed Feb. 19, 2019.
cell carcinoma with sarcomatoid features. J Clin Oncol 2019;37:4513. https://doi.org/10.1200/ 103. Reaume MN, Graham GE, Tomiak E, et al. Canadian guideline on genetic screening for hereditary renal
JCO.2019.37.15_suppl.4513 cell cancers. Can Urol Assoc J 2013;7:319-23. https://doi.org/10.5489/cuaj.1496
85. Rini BI, Plimack ER, Stus V, et al. Pembrolizumab (pembro) plus axitinib (axi) vs. sunitinib as first-line
therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/ Correspondence: Dr. Sebastien J. Hotte, Juravinski Cancer Center, Hamilton, ON, Canada;
poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study. J Clin Oncol 2019;15:4500. hotte@hhsc.ca
https://doi.org/10.1200/JCO.2019.37.15_suppl.4500

354 CUAJ • October 2019 • Volume 13, Issue 10